Suicides Hit Record High; Research Death Investigation; $43M ADHD Settlement

— News and commentary from the psychiatry world

MedicalToday
Illustration of a brain shaped maze.

The U.S. reached an all-time high during 2022, CDC data show. (Reuters)

In a randomized trial, more patients on oral antidepressants who took a had at least a 50% reduction in depression severity compared with those who received midazolam instead. (JAMA Network Open)

Federal regulators at the New York Psychiatric Institute to investigate the suicide of a study participant. (New York Times)

Linked with depression and anxiety, shift work should be considered an occupational hazard, according to researchers in, who said that the development of public health interventions that promote healthy lifestyles aimed at improving the mental health of these workers are urgently needed.

Two new validated tools may help non-clinicians rapidly diagnose . (Psychiatric Research & Clinical Practice)

The Texas Attorney General's office announced a $42.7 million over allegations that clinicians were paid to recommend the companies' attention deficit-hyperactivity disorder (ADHD) drug lisdexamfetamine dimesylate (Vyvanse).

A joint statement issued by the American Academy of Pediatrics, American College of Emergency Physicians, and the Emergency Nurses Association warns that who have psychiatric emergencies. (Pediatrics)

The launched a new initiative, Mental Health Care Works, that focuses on empowering individuals to take the first step to address their mental health.

Mental health services at senior centers used to reach older Americans with loneliness, anxiety, and substance abuse. (NPR)

Kids are , yet ADHD medications are still in a shortage. (New York Times)

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.